

PRESS RELEASE

Date: 31 August 1999

Reference: X 9903

Wilex Licences Antibody for Renal Cancer

Wilex has announced that it has acquired an exclusive licence from Centocor for the monoclonal antibody G250. Under the agreement Wilex will develop the antibody and conduct clinical trials for its use in the treatment of renal cell carcinoma, while Centocor will retain an option for product marketing rights in the U.S. If Centocor exercises this option, Wilex will receive upfront and milestone payments and will share profits.

G250 has completed Phase I clinical trials in which it showed excellent localization in renal tumors. Initial results from early Phase II trials indicate that radiolabelled G250 antibody can deliver tumor sterilizing radiation doses directly to the tumor.

According to Dr. Olaf Wilhelm, CEO of Wilex, "This acquisition is a major step for Wilex to become a prominent player in renal cancer therapy. It also adds to our growing product pipeline and shall allow Wilex to get products to the market faster."

Wilex was founded in 1997 to develop new cancer therapies which are tailored to the characteristics of patients' tumors.